LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer

References

• Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003; 21: 292–300
   PubMed Web of Science ®Google Scholar
• Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol 2000; 39: 327–33
   PubMed Web of Science ®Google Scholar
• Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 2000; 6: 3923–31
   PubMed Web of Science ®Google Scholar
• Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994; 265: 346–55
   PubMed Web of Science ®Google Scholar
• Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A 1996; 93: 15335–40
   PubMed Web of Science ®Google Scholar
• Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987; 7: 961–3
   PubMed Web of Science ®Google Scholar
• Papadakis EN, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 2000; 3: 389–92
   PubMedGoogle Scholar
• Buyru N, Tigli H, Dalay N. P53 codon 72 polymorphism in breast cancer. Oncol Rep 2003; 10: 711–4
   PubMedGoogle Scholar
• Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, et al. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 2003; 10: 307–11
   PubMedGoogle Scholar
• Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett 2004; 210: 197–203
   PubMedGoogle Scholar
• Mabrouk I, Baccouche S, El Abed R, Mokdad-Gargouri R, Mosbah A, Said S, et al. No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann N Y Acad Sci 2003; 1010: 764–70
   PubMedGoogle Scholar
• Helland A, Langerod A, Johnsen H, Olsen AO, Skovlund E, Borresen-Dale AL. p53 polymorphism and risk of cervical cancer. Nature 1998; 396: 530–1
   PubMedGoogle Scholar
• Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, et al. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005; 11: 5098–103
   PubMed Web of Science ®Google Scholar
• Han W, Kang D, Park IA, Kim SW, Bae JY, Chung KW, et al. Associations between breast cancer susceptibility gene polymorphisms and clinicopathological features. Clin Cancer Res 2004; 10: 124–30
   PubMed Web of Science ®Google Scholar
• Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002; 11: 1684–8
   PubMedGoogle Scholar
• Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BA, et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 2002; 62: 3052–7
   PubMed Web of Science ®Google Scholar
• Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, et al. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 2003; 9: 4860–4
   PubMedGoogle Scholar
• Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173–82
   PubMed Web of Science ®Google Scholar
• Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001; 61: 2505–12
   PubMed Web of Science ®Google Scholar
• Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, et al. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005; 11: 7328–33
   PubMedGoogle Scholar
• Offersen BV, Sorensen FB, Yilmaz M, Knoop A, Overgaard J. Chalkley estimates of angiogenesis in early breast cancer–relevance to prognosis. Acta Oncol 2002; 41: 695–703
   PubMed Web of Science ®Google Scholar
• Hansen LL, Andersen J, Overgaard J, Kruse TA. Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement. APMIS 1998; 106: 371–7
   PubMed Web of Science ®Google Scholar
• Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA. Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res 1998; 58: 2166–9
   PubMed Web of Science ®Google Scholar
• Wu G, Hua L, Zhu J, Mo QH, Xu XM. Rapid, accurate genotyping of beta-thalassaemia mutations using a novel multiplex primer extension/denaturing high-performance liquid chromatography assay. Br J Haematol 2003; 122: 311–6
   PubMed Web of Science ®Google Scholar
• Baccouche S, Mabrouk I, Said S, Mosbah A, Jlidi R, Gargouri A. A more accurate detection of codon 72 polymorphism and LOH of the TP53 gene. Cancer Lett 2003; 189: 91–6
   PubMedGoogle Scholar
• Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992; 22: 207–19
   PubMed Web of Science ®Google Scholar
• Hogdall EV, Hogdall CK, Christensen L, Glud E, Blaakaer J, Bock JE, et al. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res 2002; 22: 1859–64
   PubMed Web of Science ®Google Scholar